Cardiovascular
Optimizing cardiovascular disease risk screening in a low-resource setting: cost-effectiveness of program modifications in Sri Lanka modelled with nationally representative survey data
Sep
World Health Organisation. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva: World Health Organisation; 2010.
World Health Organisation. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva: World Health Organisation 2020:Licence: CC BY-NC-SA 3.0 IGO.
World Health Organization. HEARTS: Technical package for cardiovascular disease management in primary health care. Geneva: World Health Organization; 2018.
World Health Organization. HEARTS D: diagnosis and management of type 2 diabetes. Geneva: World Health Organization; 2020.
Tripathy JP, Mishra S. How effective was implementation of the package of essential non-communicable disease (PEN) interventions: A review of evidence? Diabetes Metab Syndr. 2021;15(5):102266. https://doi.org/10.1016/j.dsx.2021.102266.
Google Scholar
Singh K, Chandrasekaran AM, Bhaumik S, et al. Cost-effectiveness of interventions to control cardiovascular diseases and diabetes mellitus in South Asia: A systematic review. BMJ Open. 2018;8(4):e017809. https://doi.org/10.1136/bmjopen-2017-017809.
Google Scholar
Sharma M, John R, Afrin S, et al. Cost-Effectiveness of population screening programs for cardiovascular diseases and diabetes in low- and middle-income countries: a systematic review. Front Public Health. 2022;10:820750. https://doi.org/10.3389/fpubh.2022.820750
Moran AE, Farrell M, Cazabon D, et al. Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries. Rev Panam Salud Publica. 2022;46:e140. https://doi.org/10.26633/rpsp.2022.140
Lee JT, Lawson KD, Wan Y, et al. Are cardiovascular disease risk assessment and management programmes cost effective? A systematic review of the evidence. Prev Med. 2017;99:49–57. https://doi.org/10.1016/j.ypmed.2017.01.005.
Google Scholar
D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 2008;117(6):743–53.
Google Scholar
World Health Organization. Prevention of Cardiovascular Disease: Pocket Guidelines for Assessment and Management of Total Cardiovascular Risk. (WHO/ISH Cardiovascular Risk Prediction Charts for WHO epidemiological sub-regions SEAR B, SEAR D). Geneva: WHO, 2007.
Zhang Y, Miao H, Chia YC, et al. Cardiovascular risk assessment tools in Asia. J Clin Hypertens (Greenwich). 2022;24(4):369–77. https://doi.org/10.1111/jch.14336.
Google Scholar
Olayemi E, Asare EV, Benneh-Akwasi Kuma AA. Guidelines in lower-middle income countries. Br J Haematol. 2017;177(6):846–54. https://doi.org/10.1111/bjh.14583.
Google Scholar
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997–2007.
Google Scholar
NICE. Costing report: Lipid modification. Implementing the NICE guideline on lipid modification (CG181). Manchester: NICE; 2014.
U. S. Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016;316(19):1997–2007. https://doi.org/10.1001/jama.2016.15450
Ministry of Health. Cardiovascular Risk Management (Total Cardiovascular Risk Assessment Approach). Guidelines for Primary Health Care providers. Colombo: Ministry of Health 2018.
Enas EA, Dharmarajan TS. The Lipid Association of India (LAI) Expert Consensus Statement on Management of Dyslipidemia in Indians 2016: A Giant Leap Forward! J Assoc Physicians India 2016;64(6):102.
Yebyo HG, Zappacosta S, Aschmann HE, et al. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: A benefit-harm balance modelling study. BMC Cardiovasc Disord. 2020;20(1):418. https://doi.org/10.1186/s12872-020-01697-6.
Google Scholar
Organization WH. Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization; 2021.
Murphy A, Faria-Neto JR, Al-Rasadi K, et al. World Heart Federation Cholesterol Roadmap. Glob Heart. 2017;12(3):179–97.e5. https://doi.org/10.1016/j.gheart.2017.03.002.
Google Scholar
Ray KK, Ference BA, Severin T, et al. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022;17(1):75. https://doi.org/10.5334/gh.1154.
Google Scholar
Mallawaarachchi DV, Wickremasinghe SC, Somatunga LC, et al. Healthy Lifestyle Centres: a service for screening noncommunicable diseases through primary health-care institutions in Sri Lanka. WHO South-East Asia Journal of Public Health. 2016;5(2):89–95.
Google Scholar
Ministry of Health. Annual Health Bulletin, 2019. Colombo: Ministry of Health; 2021.
Ministry of Health. National Policy and Strategic Framework on Cancer Prevention & Control. Colombo: Ministry of Health, 2014.
Rannan-Eliya RP, Wijemunige N, Perera P, et al. Prevalence and associations of hypertension in Sri Lankan adults: Estimates from the SLHAS 2018–19 survey using JNC7 and ACC/AHA 2017 guidelines. Glob Heart. 2022;17(1):50. https://doi.org/10.5334/gh.1135.
Google Scholar
Wijemunige N, Rannan-Eliya RP, Maurer J, et al. Cost-effectiveness and distributional impact of opportunistic screening for people at high-risk of cardiovascular disease in Sri Lanka: A modelling study. Glob Heart. 2022;17(1):89. https://doi.org/10.5334/gh.1174.
Google Scholar
WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332–45. https://doi.org/10.1016/S2214-109X(19)30318-3.
Google Scholar
Ueda P, Woodward M, Lu Y, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 2017;5(3):196–213.
Google Scholar
Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2020.
Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057–62. https://doi.org/10.1161/CIRCULATIONAHA.108.784215.
Google Scholar
Sun Y, Lee SH, Heng BH, et al. 5-year survival and rehospitalization due to stroke recurrence among patients with hemorrhagic or ischemic strokes in Singapore. BMC Neurol. 2013;13:133. https://doi.org/10.1186/1471-2377-13-133.
Google Scholar
World Health Organization. Life Tables by country (GHE: Life tables). 16/12/2020 ed: World Health Organization, Global Health Observatory, 2020.
Perel P, Avezum A, Huffman M, et al. Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: The World Heart Federation roadmap for secondary prevention of cardiovascular disease. Glob Heart. 2015;10(2):99–110. https://doi.org/10.1016/j.gheart.2015.04.003.
Google Scholar
Kularatna S, Chen G, Byrnes J, et al. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L value sets. Value Health Reg Issues. 2017;12:20–3. https://doi.org/10.1016/j.vhri.2017.01.001.
Google Scholar
Institute for Health Policy. IHP Analaysis of Registrar General’s Mortality Data, Sri Lanka. Sri Lanka: Registrar General’s Department; 2015.
Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109–24. https://doi.org/10.1093/qjmed/hcq165.
Google Scholar
Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(1):28–36. https://doi.org/10.1001/jamainternmed.2017.6015.
Google Scholar
Amarasinghe SN, Dalpatadu KCS, Rannan-Eliya RP. Sri Lanka Health Accounts: National Health Expenditure 1990–2019. Colombo: Institute for Health Policy 2021.
Perera C, Rannan-Eliya RP, Senanayake S, et al. Public Hospital Inpatient Discharge Survey 2005. Colombo: Institute for Health Policy, 2006.
Turner HC, Lauer JA, Tran BX, et al. Adjusting for inflation and currency changes within health economic studies. Value Health. 2019;22(9):1026–32. https://doi.org/10.1016/j.jval.2019.03.021.
Google Scholar
Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–24. https://doi.org/10.2471/BLT.14.138206.
Google Scholar
Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–35. https://doi.org/10.1016/j.jval.2016.02.017.
Google Scholar
Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health 2018;3(6):e000964. doi: https://doi.org/10.1136/bmjgh-2018-000964
Kazibwe J, Gheorghe A, Wilson D, et al. The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review. Value Health. 2022;25(3):385–9. https://doi.org/10.1016/j.jval.2021.08.014.
Google Scholar
World Bank. World Development Indicators. Washington (DC): World Bank Group, 2022.
Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314(2):142–50. https://doi.org/10.1001/jama.2015.6822.
Google Scholar
Smith L, Atherly A, Campbell J, et al. Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk. BMC Public Health. 2019;19(1):1234. https://doi.org/10.1186/s12889-019-7573-8.
Google Scholar
Heller DJ, Coxson PG, Penko J, et al. Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke. Circulation. 2017;136(12):1087–98. https://doi.org/10.1161/circulationaha.117.027067.
Google Scholar
Fontana M, Asaria P, Moraldo M, et al. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation. 2014;129(24):2539–46. https://doi.org/10.1161/CIRCULATIONAHA.113.007595.
Google Scholar
Hutchins R, Viera AJ, Sheridan SL, et al. Quantifying the utility of taking pills for cardiovascular prevention. Circ Cardiovasc Qual Outcomes. 2015;8(2):155–63. https://doi.org/10.1161/CIRCOUTCOMES.114.001240.
Google Scholar
Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10–31. https://doi.org/10.1016/j.jval.2021.10.008.
Google Scholar
Heidenreich PA, Clarke SL, Maron DJ. Time to relax the 40-year age threshold for pharmacologic cholesterol lowering. J Am Coll Cardiol. 2021;78(20):1965–7. https://doi.org/10.1016/j.jacc.2021.08.072.
Google Scholar
Chou R, Cantor A, Dana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2022;328(8):754–71. https://doi.org/10.1001/jama.2022.12138.
Google Scholar
Epstein D, García-Mochón L, Kaptoge S, et al. Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. Eur J Health Econ. 2016;17(8):1041–53. https://doi.org/10.1007/s10198-015-0753-2.
Google Scholar
Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33–64. https://doi.org/10.1016/s0167-6296(96)00507-3.
Google Scholar
Grover SA, Coupal L, Lowensteyn I. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate? Can J Cardiol. 2008;24(4):261–6. https://doi.org/10.1016/s0828-282x(08)70174-0.
Google Scholar
Hiligsmann M, Wyers CE, Mayer S, et al. A systematic review of economic evaluations of screening programmes for cardiometabolic diseases. Eur J Public Health. 2017;27(4):621–31. https://doi.org/10.1093/eurpub/ckw237.
Google Scholar
Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. https://doi.org/10.1007/s11883-012-0291-7.
Google Scholar
Capuno J, Kraft A, O’Donnell O. Effectiveness of clinic-based cardiovascular disease prevention: a randomized encouragement design experiment in the Philippines. Soc Sci Med. 2021;283:114194. https://doi.org/10.1016/j.socscimed.2021.114194
Sarkar S. The devastating health consequences of Sri Lanka’s economic collapse. BMJ. 2022;377:o1543. https://doi.org/10.1136/bmj.o1543
Matthias AT, Jayasinghe S. Worsening economic crisis in Sri Lanka: impacts on health. Lancet Global Health. 2022;10(7):e959. https://doi.org/10.1016/S2214-109X(22)00234-0
Riley L, Guthold R, Cowan M, et al. The World Health Organization STEPwise approach to noncommunicable disease risk-factor surveillance: methods, challenges, and opportunities. Am J Public Health. 2016;106(1):74–8. https://doi.org/10.2105/AJPH.2015.302962.
Google Scholar
Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–30. https://doi.org/10.2471/BLT.15.164418.
Google Scholar
Basu S, Wagner RG, Sewpaul R, et al. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. Lancet Glob Health. 2019;7(2):e270–80. https://doi.org/10.1016/s2214-109x(18)30450-9.
Google Scholar
